RxDoctor Payments Data

Kristin Boyd

Family · South Charleston, WVNPI 1649958257

Payments from drug & device makers

$4,755in general payments, 2019–2025

Across 191 payments — averaging $24.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$840
  • GSK$588
  • Axsome Therapeutics, Inc.$400
  • Boehringer Ingelheim$315
  • Sanofi$273
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,755100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,755 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$19,392
Medicare patients
233
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$136,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$45,185
Breo ElliptaFluticasone/Vilanterol58$37,358
SymbicortBudesonide/Formoterol Fumarate104$36,363
Spiriva RespimatTiotropium Bromide44$34,097
Spiriva HandihalerTiotropium Bromide22$16,738
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$16,255
Incruse ElliptaUmeclidinium Bromide29$15,759
Albuterol Sulfate HfaAlbuterol Sulfate411$15,330
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate54$11,460
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$8,795
BreynaBudesonide/Formoterol Fumarate33$6,529
Varenicline Tartrate18$3,833
Ventolin HfaAlbuterol Sulfate59$3,772
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$3,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$588$202,470236 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,036$81,548154 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$315$50,35269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →